Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and Efficacy of Droxidopa for Fatigue in Patients With Parkinsonism

Trial Profile

Safety and Efficacy of Droxidopa for Fatigue in Patients With Parkinsonism

Status: Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 07 Mar 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Droxidopa (Primary)
  • Indications Fatigue; Parkinson's disease
  • Focus Therapeutic Use

Most Recent Events

  • 14 Feb 2022 Status changed from not yet recruiting to withdrawn prior to enrolment.
  • 11 Aug 2021 Planned initiation date changed from 1 Jul 2021 to 1 Dec 2021.
  • 19 Apr 2021 Planned End Date changed from 1 Jan 2021 to 1 Jul 2023.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top